Genomic aberration status, histology, performance status, and stage of disease are key factors that influence the treatment of non-small-cell lung cancer (NSCLC). The characterization of biomarker-defined patient populations and the FDA and EC approval of a number targeted therapies in 2015 have positioned NSCLC at the forefront of personalized medicine in oncology, and have resulted in an evolving treatment landscape for the disease. This analysis provides insight on current use of approved therapies for NSCLC in the EU5 and oncologists’ perception of these therapies.
Non-Small-Cell Lung Cancer - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (EU5)
This report is available to find out more click the link and fill out the form to get more details.
Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need remains a key area of focus for drug developers.
Non-Small-Cell Lung Cancer - Current Treatment - Detailed, Expanded Analysis (EU5) - 2020
The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has r...
Non-Small-Cell Lung Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Squamous NSCLC (US/EU)
The preferred initial treatment for metastatic squamous non-small-cell lung cancer (NSCLC), regardless of PD-...